Symbols

CMPS

COMPASS Pathways·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 4

Bearish signal 1

Stock Price Surged Significantly

Consensus Rating "Buy"

MACD Golden Cross

Significant Net Income Decline

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CMPS

Compass Pathways Plc

A UK developer of psilocybin therapy for the treatment of resistant depression

Industry

Pharmaceutical

Established Date

Listing Date

09/18/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

166

Fiscal Year Ends

12-31

Website

www.compasspathways.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

33 Broadwick Street, London W1F 0DQ, United Kingdom

Business

Introduction

COMPASS Pathways plc is incorporated in England and Wales. COMPASS Pathways plc is a mental health care company that promotes patient access to evidence-based mental health care innovations. The company is motivated by the need to find better ways to help and empower people with mental health challenges who are not helped by existing therapies, and is pioneering a new psilocybin treatment model that combines psilocybin with psychological support.

Earnings Call

Q1/2025

Estimate EPS-0.49

Actual EPS-0.24

Estimate Revenue--

Actual Revenue0

Contradictions in Focus: COMPASS Pathways' 2025 Q1 Earnings Call Reveals Conflicting Views on Suicidality and Manufacturing Expansion

May 19,2025 10:17·
Earnings Decrypt

Q2/2025

Estimate EPS-0.36

Actual EPS-0.41

Estimate Revenue--

Actual Revenue0

Navigating Contradictions: COMPASS Pathways' Q2 2025 Earnings Call Reveals Uncertainties in FDA Engagement and Regulatory Strategy

Jul 31,2025 10:41·
Earnings Decrypt

Company Financials

EPS

CMPS has released its 2025 Q3 earnings. EPS was reported at -1.44, versus the expected -0.41, missing expectations. The chart below visualizes how CMPS has performed over recent quarters, highlighting trends in earnings surprises.